1. Home
  2. ETNB vs ECC Comparison

ETNB vs ECC Comparison

Compare ETNB & ECC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETNB
  • ECC
  • Stock Information
  • Founded
  • ETNB 2018
  • ECC N/A
  • Country
  • ETNB United States
  • ECC United States
  • Employees
  • ETNB N/A
  • ECC N/A
  • Industry
  • ETNB Biotechnology: Pharmaceutical Preparations
  • ECC
  • Sector
  • ETNB Health Care
  • ECC
  • Exchange
  • ETNB Nasdaq
  • ECC NYSE
  • Market Cap
  • ETNB 864.2M
  • ECC 966.1M
  • IPO Year
  • ETNB 2019
  • ECC N/A
  • Fundamental
  • Price
  • ETNB $6.31
  • ECC $8.85
  • Analyst Decision
  • ETNB Buy
  • ECC Buy
  • Analyst Count
  • ETNB 7
  • ECC 2
  • Target Price
  • ETNB $30.33
  • ECC $11.00
  • AVG Volume (30 Days)
  • ETNB 1.3M
  • ECC 679.0K
  • Earning Date
  • ETNB 02-27-2025
  • ECC 02-22-2024
  • Dividend Yield
  • ETNB N/A
  • ECC 19.16%
  • EPS Growth
  • ETNB N/A
  • ECC 369.44
  • EPS
  • ETNB N/A
  • ECC 1.69
  • Revenue
  • ETNB N/A
  • ECC $122,654,279.00
  • Revenue This Year
  • ETNB N/A
  • ECC $36.58
  • Revenue Next Year
  • ETNB N/A
  • ECC $12.88
  • P/E Ratio
  • ETNB N/A
  • ECC $5.93
  • Revenue Growth
  • ETNB N/A
  • ECC 96.41
  • 52 Week Low
  • ETNB $5.99
  • ECC $8.60
  • 52 Week High
  • ETNB $16.63
  • ECC $11.79
  • Technical
  • Relative Strength Index (RSI)
  • ETNB 31.27
  • ECC 41.07
  • Support Level
  • ETNB $5.99
  • ECC $8.83
  • Resistance Level
  • ETNB $6.65
  • ECC $8.99
  • Average True Range (ATR)
  • ETNB 0.40
  • ECC 0.14
  • MACD
  • ETNB -0.14
  • ECC 0.00
  • Stochastic Oscillator
  • ETNB 15.70
  • ECC 42.54

About ETNB 89bio Inc.

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

About ECC EAGLE POINT CREDIT CO LLC

Eagle Point Credit Co Inc is an externally managed, non-diversified closed-end management investment company.

Share on Social Networks: